Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Qiagen NV
Having licensed rights to Movantik from AstraZeneca in February, RedHill has now offloaded EU rights to Cosmo. Calliditas to obtain PBC candidate in bid to acquire Genkyotex.
Qiagen's shareholders said Thermo Fisher's final offer price for the diagnostics company was too low.
A PwC analysis finds biopharma aggregate deal value declined 87% during the first half compared to the second half of 2018; deal volume dropped 17%. The pandemic was a cause, but not the only factor.
It has taken a while but European regulators have finally followed their US counterparts and approved Piqray, making it the first targeted medicine for HR+/HER2- advanced breast cancer with a PIK3CA mutation.
Research, Analytical Equipment & Supplies
- PCR & Amplification Tools
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
Drug Discovery Tools
- Other Names / Subsidiaries
- Amnisure International LLC
- Biobase, Biotage
- Corbett Life Science Pty. Ltd.
- Digene Corporation
- eGene, Inc.
- ESE GmbH
- Ingenuity Systems Inc
- Genaco Biomedical Products, Inc.
- MO BIO Laboratories
- OmicSoft Corporation
- SABiosciences Corporation
- Ipsogen S.A.
- Qiagen Manchester Limited
- Qiagen N.V.
- Xeragon Inc.